Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Korte, A. Rolf, W. Seeger, A. Ghofrani, R. Voswinckel (Giessen, Bad Nauheim, Germany). Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension. Eur Respir J 2013; 42: Suppl. 57, 4058

Member's Comments

No comment yet.

Related content which might interest you: Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension Source: Eur Respir J 2012; 40: 1410-1419 Year: 2012 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Challenges in the diagnosis and treatment of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 313-320 Year: 2012 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy? Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Effects of oral dual ERA therapy on pulmonary function testing and 6MWT in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary circulation Year: 2007 The value of cardiopulmonary exercise test in assessment of the severity of pulmonary arterial hypertension patients Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Heart rate recovery in response to disease targeted therapy in pre-capillary pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Prognostic value of hemodynamics following treatment initiation in pulmonary arterial hypertension Source: International Congress 2017 – Cardiac function assessment in pulmonary hypertension Year: 2017 Pressure-flow relationship during exercise predicts transplant-free survival in patients with pre-capillary pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: new pathophysiological insights Year: 2015